Intrust Bank NA Has $1.35 Million Holdings in Sanofi (NASDAQ:SNY)

Intrust Bank NA increased its position in shares of Sanofi (NASDAQ:SNY) by 5.2% in the 4th quarter, HoldingsChannel reports. The firm owned 27,978 shares of the company’s stock after acquiring an additional 1,391 shares during the quarter. Intrust Bank NA’s holdings in Sanofi were worth $1,349,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Raymond James Financial Inc. bought a new position in shares of Sanofi in the 4th quarter valued at $135,933,000. Boston Partners boosted its stake in Sanofi by 86.4% in the fourth quarter. Boston Partners now owns 5,396,531 shares of the company’s stock valued at $260,607,000 after buying an additional 2,501,073 shares in the last quarter. Magnetar Financial LLC grew its position in Sanofi by 104.3% in the fourth quarter. Magnetar Financial LLC now owns 3,340,317 shares of the company’s stock valued at $161,103,000 after acquiring an additional 1,705,148 shares during the last quarter. DAVENPORT & Co LLC lifted its holdings in shares of Sanofi by 40.7% in the fourth quarter. DAVENPORT & Co LLC now owns 2,295,569 shares of the company’s stock worth $110,715,000 after acquiring an additional 664,455 shares during the last quarter. Finally, Thrivent Financial for Lutherans lifted its holdings in shares of Sanofi by 36.0% in the fourth quarter. Thrivent Financial for Lutherans now owns 1,943,761 shares of the company’s stock worth $93,774,000 after acquiring an additional 514,542 shares during the last quarter. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on SNY. The Goldman Sachs Group initiated coverage on shares of Sanofi in a research report on Friday, March 21st. They set a “neutral” rating and a $65.00 price objective for the company. Sanford C. Bernstein raised Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Finally, StockNews.com lowered Sanofi from a “buy” rating to a “hold” rating in a research note on Thursday, December 12th. Three investment analysts have rated the stock with a hold rating, one has assigned a buy rating and two have given a strong buy rating to the stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $62.50.

Sanofi Price Performance

Shares of NASDAQ:SNY opened at $55.82 on Friday. The firm has a market cap of $141.66 billion, a PE ratio of 22.42, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. Sanofi has a 52 week low of $45.22 and a 52 week high of $60.12. The firm’s fifty day moving average is $55.13 and its 200-day moving average is $52.79. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46.

Sanofi (NASDAQ:SNY) last released its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, meeting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. Sell-side analysts predict that Sanofi will post 4.36 earnings per share for the current year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.